TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Arcutis Biotherapeutics, Inc.
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Arcutis Biotherapeutics has submitted a supplemental New Drug Application to the FDA for ZORYVE cream 0.3%, seeking approval to treat plaque psoriasis in children ages 2 to 5. If approved by the June 29, 2026 target date, it would be the first topical PDE4 inhibitor for this age group.

Insights
ADP   positive

Trusted enterprise HR solutions, 50-year dividend growth history, resilient business model in human resources management


ARQT   positive

Company is expanding treatment options for children, demonstrating innovation in dermatological care and potential market expansion